Evidence map›Paper›PMID 35445808›Full record

Trial reportInternational urogynecology journal2022

Effect of combined use of tolterodine and continuous positive airway pressure vs continuous positive airway pressure only treatment on overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome: a randomized clinical trial.

Kasım Ertaş, Hanifi Yıldız, Murat Demir, Rahmi Aslan, Recep Eryılmaz, Şevder Kırmızıtoprak, Kerem Taken

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urogynecology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kasım ErtaşDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey. drkasim_ertas@hotmail.com.ORCID 0000-0003-4300-1399
Hanifi YıldızDepartment of Chest Diseases, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
Murat DemirDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey.
Rahmi AslanDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey.
Recep EryılmazDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey.
Şevder KırmızıtoprakDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey.
Kerem TakenDepartment of Urology, Faculty of Medicine, Van Yuzuncu Yil University, 65090, Van, Tuşba, Turkey.
Van Yüzüncü Yıl Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisObstructive sleep apnea syndrome is associated with urological symptoms, including overactive bladder (OAB). This study aims to determine whether combined tolterodine and CPAP therapies are more effective for patients with OSAS than CPAP treatment only.

methodsWomen who underwent polysomnography test and were diagnosed with moderate-to-severe OSAS with apnea-hypopnea index (AHI) were included in the study. Data were collected on AHI, OAB awareness-8-item tool (OAB-V8), incontinence questionnaire-urinary incontinence short form (ICIQ-UI-SF), total daily urine volume (DUV), and the Benefit, satisfaction with treatment and willingness (BSW) tool. Eligible patients were randomized to receive either CPAP treatment only or combined CPAP and tolterodine treatment for 3 months.

resultsAmong 103 participants, a total of 60 were included. Patients in both treatment arms showed significant improvements in OAB-V8, ICIQ-UI-SF, and total DUV compared to their baseline. The mean OAB-V8 was 15.7 at baseline and 5.6 at 3 months for the combined treatment arm and 16.6 and 7.6 at 3 months for the CPAP group only (mean baseline-adjusted between-group difference -1.1 [95% CI, -12.3 to -7.4]; p < 0.001). The improvement in the mean ICIQ-UI-SF was also statistically more significant in the combined therapy group than in the CPAP only arm (mean baseline-adjusted between-group difference -3.27 [95% CI, -4.6 to -1.59]; p < 0.001). No statistical significance was found in the improvement of total DUV between the groups.

conclusionsIn this study, combined use of tolterodine with CPAP provides beneficial effects to CPAP treatment only regarding OAB symptoms. Further research is required to confirm these findings in a large cohort.

Indexed as

Sleep Apnea, ObstructiveUrinary Bladder, OveractiveUrinary IncontinenceContinuous Positive Airway PressureFemaleHumansPolysomnographyTolterodine TartrateTolterodine TartrateContinuous positive airway pressureObstructive sleep apnea syndromeOveractive bladderTolterodine

Identifiers

PMID35445808
OpenAlexW4224297964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.